The anticancer potential of chemical constituents of Moringa oleifera targeting CDK-2 inhibition in estrogen receptor positive breast cancer using in-silico and in vitro approches

Most of the breast cancers are estrogen receptor-positive recurring with a steady rate of up to 20 years dysregulating the normal cell cycle. Dinaciclib is still in clinical trials and considered as a research drug against such cancers targeting CDK2. The major goal of this study was to identify the...

Descripción completa

Detalles Bibliográficos
Autores principales: Sultan, Rida, Ahmed, Abrar, Wei, Li, Saeed, Hamid, Islam, Muhammad, Ishaq, Muhammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625284/
https://www.ncbi.nlm.nih.gov/pubmed/37925393
http://dx.doi.org/10.1186/s12906-023-04198-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625284/
https://www.ncbi.nlm.nih.gov/pubmed/37925393
http://dx.doi.org/10.1186/s12906-023-04198-z

Ejemplares similares